AXLRx Book a callCommission

Rare Disease · United Kingdom · In-Market

UK Spinal Muscular Atrophy Competitive Intelligence

All three SMA therapies cleared NICE with confidential PAS. The UK's 2021 newborn screening programme is now the real access lever, shifting competition to physician and family preference.

Assess this report View Sample Brief Reviewed by Naresh Gupta, Founder & Director Last updated August 2026
Market United States GCC (Gulf) United Kingdom Stage

Key takeaways

  • 6 NHS-designated newborn-screening centres delivering Zolgensma to pre-symptomatic infants identified via the UK's 2021 SMA NBS programme — the first national SMA screening programme in Europe
  • ~300 UK SMA patients currently on nusinersen (Spinraza) — mainly Type 2/3 adults outside Zolgensma's age/weight eligibility window
  • $2.125M Zolgensma's WAC, accepted by NICE under a confidential Patient Access Scheme negotiated through the HST15 appraisal (2021) and later expanded to presymptomatic infants under HST24 (2023)

All three SMA agents cleared NICE with confidential PAS; the UK's 2021 newborn screening programme now shifts competition to physician and family preference, not access.

An estimated 1,000 UK patients live with spinal muscular atrophy across all types. The UK added SMA to its national newborn screening programme in 2021, the first national NBS programme for SMA in Europe, identifying roughly 25 pre-symptomatic patients per year and routing them to one of 6 specialist centres for early treatment. NICE has recommended all three approved SMA therapies through confidential Patient Access Scheme agreements: Zolgensma (onasemnogene abeparvovec), recommended via the Highly Specialised Technology route under NICE HST15 (2021) and expanded to the pre-symptomatic population under HST24 (2023), for Type 1 and pre-symptomatic patients with 3 or fewer SMN2 copies; Spinraza (nusinersen, NICE TA588, 2019), an intrathecal ASO, for Types 1–3; and Evrysdi (risdiplam, NICE TA755, 2022), an oral SMN2 modifier increasingly preferred by families avoiding intrathecal dosing.

The NHS treatment algorithm is now type- and age-based rather than access-based: Type 1 and NBS-identified pre-symptomatic patients under 2 years route to Zolgensma; Type 2/3 patients under 18 choose between nusinersen and risdiplam; Type 2/3 adults choose between risdiplam and nusinersen. All three agents carry confidential PAS pricing, so relative NHS net cost is commercially sensitive, but Zolgensma's cost-effectiveness case for its $2.125 million WAC was only accepted under a confidential commercial arrangement negotiated through the HST15 appraisal (2021), later expanded to presymptomatic infants under HST24 (2023) — illustrating how tightly NICE's cost-effectiveness ceiling constrains one-time gene-therapy pricing even in an ultra-rare, high-unmet-need indication. Nusinersen remains the default for roughly 300 UK patients, largely Type 2/3 adults outside Zolgensma's age/weight eligibility, while risdiplam's oral dosing is winning share in community settings by reducing the intrathecal procedure burden.

Approved Spinal Muscular Atrophy agents — UK, 2026

DRUG LANDSCAPE
Drug (Brand / INN)MechanismCompanyUK Approval / NICE StatusKey Trial ResultNHS Commissioning Status
Zolgensma (onasemnogene abeparvovec)One-time gene therapy IVNovartis Gene TherapiesMHRA approved; NICE HST15 recommended with PAS (2021), expanded under HST24 (2023)STR1VE / NURTURE trials; NICE HST15/HST24 recommend for Type 1 and pre-symptomatic (≤3 SMN2 copies)NHS commissioned; Managed Access Agreement; ~50–60 patients/year treated at 6 NBS centres
Spinraza (nusinersen)Intrathecal antisense oligonucleotideBiogenMHRA approved; NICE TA588 recommended with PAS (2019)ENDEAR / CHERISH trials; NICE TA588 recommends for Types 1–3NHS HSS commissioned; ~300 UK patients, mainly Type 2/3 adults
Evrysdi (risdiplam)Oral SMN2 splicing modifierRocheMHRA approved; NICE TA755 recommended with PAS (2022)FIREFISH / SUNFISH trials; NICE TA755 recommends with PASNHS commissioned; growing share in Type 2/3 community-based patients

Sources: MHRA public assessment reports; NICE HST15 (Zolgensma, 2021) and HST24 (Zolgensma update, 2023); NICE TA588 (Spinraza, 2019); NICE TA755 (Evrysdi, 2022); NHS England SMA commissioning policy 2023; UK newborn screening programme SMA data 2023.

What this brief answers

Every section answers a named commercial question your team is asking, scoped to your asset.

  1. How is NHS England's 2021 newborn screening programme changing the point of first prescribing decision for Zolgensma versus nusinersen and risdiplam? • NBS-to-treatment referral pathway at the 6 designated centres • pre-symptomatic eligibility criteria (≤3 SMN2 copies) • real-world uptake since the 2021 launch
  2. What is the confidential PAS pricing structure behind each of the three NICE-recommended SMA agents, and how did Zolgensma's HST appraisal accommodate its $2.125 million WAC? • NICE HST15/HST24 (Zolgensma), TA588 (Spinraza), and TA755 (Evrysdi) PAS precedent and cost-effectiveness modelling • comparative net-price analysis methodology • managed access data-collection obligations
  3. Why are UK families and physicians increasingly choosing oral risdiplam over intrathecal nusinersen for Type 2/3 patients, and what does that mean for each drug's addressable NHS population? • Comparative prescribing share data across NHS SMA centres • tolerability and administration-burden drivers behind the shift • risdiplam's growth trajectory in community settings
What's inside

Rare Disease · 24–32 pp · In-Market · Analyst report + Excel model + PowerPoint readout

  1. 1 · Market Map & NHS Newborn Screening Pathway 4 pp
    • [object Object]
    • [object Object]
  2. 2 · Competitive Drug Profiles (3 agents) 7 pp
    • [object Object]
    • [object Object]
  3. 3 · NHS Treatment Algorithm — Type & Age-Based Routing 4 pp
    • [object Object]
    • [object Object]
  4. 4 · NICE PAS Pricing & Cost-Effectiveness Precedent 5 pp
    • [object Object]
    • [object Object]
  5. 5 · NBS Centre Network & Prescriber Landscape 3 pp
    • [object Object]
    • [object Object]
  6. 6 · Oral vs Intrathecal Share Shift — Risdiplam Growth 3 pp
    • [object Object]
    • [object Object]

Appendix and source ledger included · 45-minute analyst readout included with delivery

Custom brief delivered in 72 hours.

Assess this report

Included with every brief

PDF
PDF Brief
Spinal Muscular Atrophy CI Brief — Complete Edition
25–30 page analyst brief: competitive drug profiles, NICE PAS pricing analysis for the UK market, newborn screening pathway, and prescriber share dynamics.
XLS
Excel Model
Drug Comparison & NHS Commissioning Grid
Drug comparison table, NICE appraisal tracker, and NHS commissioning grid in editable Excel format.
PPT
PowerPoint
Executive Readout — PowerPoint
12–15 slide readout deck for commercial team presentations, formatted to AXLRx design standards.

Get Started

Commission this brief

AXLRx delivers Spinal Muscular Atrophy competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams targeting the UK market. Custom brief in 72 hours.

  1. 1. Submit your requestUse the intake form to specify your indication, geography, and commercial question.
  2. 2. Scoping callAXLRx analyst confirms scope, comparators, and delivery format.
  3. 3. DeliveryResearch-verified brief in 72 hours with optional analyst readout.
Assess this report View sample briefs

How AXLRx builds this brief

Prepared by MoatRx analysts on the AXLRx commercial consulting engine.

Every AXLRx brief is built from primary regulatory sources (MHRA, NICE, NHS England), peer-reviewed literature, and live NHS commissioning documentation — not secondary summaries. Findings are independently verified before inclusion.

Spinal Muscular Atrophy UK CI sources: MHRA public assessment reports, NICE HST15 (2021) and HST24 (2023) for Zolgensma, NICE TA588 (2019) for Spinraza, NICE TA755 (2022) for Evrysdi, NHS England SMA commissioning policy (2023), and UK newborn screening programme SMA data (2023).

  • Drug approval dates verified against MHRA public assessment reports and NICE technology appraisal documents
  • Clinical trial results verified against published primary sources and trial registries
  • NICE appraisal and PAS status verified against the current NICE appraisal tracker (nice.org.uk)
  • NHS newborn screening and commissioning data verified against NHS England SMA commissioning policy documentation

Frequently asked questions

Deliverables What formats are included with every brief?

Every commissioned brief includes three deliverables: a 20–30 page PDF analyst brief with verified sources and exhibit tables, an editable Excel model (drug comparison grid, payer formulary data, or patient flow model — depending on deliverable type), and a 10–15 slide PowerPoint readout deck formatted for commercial team presentations. An optional 60-minute analyst readout call is included with all deliveries.

Sources What sources does AXLRx use, and how are findings verified?

AXLRx builds from primary sources only: MHRA public assessment reports, the NICE highly specialised technology and technology appraisal decisions for each approved agent, NHS England SMA commissioning policy, and UK newborn-screening programme data. No secondary summaries or market research reports. Every factual claim is independently verified before inclusion. Source citations are provided for all key data points in the delivered brief.

Customisation Can I tailor the brief to my specific question, geography, or comparator set?

Yes. The intake form captures your indication, target geography, key comparator drugs, and the specific commercial question you need answered. A scoping call confirms scope before research starts. Custom extensions (additional payer markets, pipeline agent profiles, or country-specific deep-dives) can be added to any standard brief. Commission via the intake form to start.